Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2332)	3/2/2018 2:33:04 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Why? There was no harm to Eylea US sale for jan-feb period, and there was not at all any problem for ex-US. Bloomberg article was PAID/ORCESTERED by someone who wanted to spread fear about Eylea future, after it dominate in US and ex-US 4Q. And will continue to dominate in 2018/19....unless there is restriction in CMS part B program. I was surprise that there was not even more positive trend, regardless sell off in general market. Fear from CVOT uncertainty is present.